Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00798213 | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | terminated | Phase 2 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2015 | clinicaltrials |
| NCT00104364 | A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED) | completed | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00106145 | A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) | completed | Phase 1 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00500006 | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | terminated | Phase 1 | 3 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00723827 | Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) | completed | — | 682 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00405054 | A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) | terminated | Phase 2 | 52 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2015 | clinicaltrials |
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 22, 2015 | clinicaltrials |
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) | terminated | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 21, 2015 | clinicaltrials |
| NCT01220570 | The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) | completed | Phase 1 | 63 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 21, 2015 | clinicaltrials |
| NCT00092495 | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) | completed | Phase 3 | 3,055 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 13, 2015 | clinicaltrials |
| NCT00736333 | A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | completed | — | 167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 5, 2014 | clinicaltrials |
| NCT00827177 | Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 87 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jan 24, 2014 | clinicaltrials |
| NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen | withdrawn | Phase 2 | 0 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Jan 7, 2014 | clinicaltrials |
| NCT01225536 | Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations | completed | Phase 1 | 24 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | May 3, 2013 | clinicaltrials |
| NCT00622063 | An Extension Study for Patients Previously Treated With ARQ 501 | completed | Phase 1 / Phase 2 | 1 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 167 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 6 | Feb 28, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00558207 | A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 2 | 43 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Feb 25, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2012 | clinicaltrials |
| NCT00612209 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors(ARQ 197) | completed | Phase 1 | 51 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jul 23, 2012 | clinicaltrials |
| NCT00612703 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jul 23, 2012 | clinicaltrials |
| NCT00874042 | Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 74 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jul 23, 2012 | clinicaltrials |
| NCT00802555 | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 21 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Jul 12, 2012 | clinicaltrials |
| NCT01226901 | A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) | terminated | Phase 1 | 3 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2012 | clinicaltrials |
| NCT00524524 | An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Oct 19, 2011 | clinicaltrials |
| NCT00825487 | Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies | completed | Phase 1 | 50 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Oct 19, 2011 | clinicaltrials |
| NCT00302172 | ARQ 197 in Subjects With Metastatic Solid Tumors | completed | Phase 1 | 78 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Aug 26, 2009 | clinicaltrials |
| NCT00102700 | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | completed | Phase 2 | 66 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 29, 2009 | clinicaltrials |
| NCT00310518 | Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma | completed | Phase 2 | 30 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 29, 2009 | clinicaltrials |
| NCT00075933 | ARQ 501 in Subjects With Cancer | completed | Phase 1 | 80 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00099190 | ARQ 501 in Combination With Docetaxel in Patients With Cancer | completed | Phase 1 | 50 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00358930 | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 60 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00106626 | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | completed | Phase 1 | 52 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 22, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials